• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-09

  The PKH26 Red Fluorescent Cell Linker Kit supports stable red-fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation studies. It is intended for membrane-focused applications in vitro and in vivo, not for intracellular targets or non-membrane structures.

• Moxidectin–Polyene Synergy in Oral Candidiasis

  2026-08-08

  Ye et al. show that moxidectin potentiates amphotericin B and Nystatin by increasing Candida albicans ergosterol, thereby strengthening polyene binding and antifungal activity. Transcriptomic, genetic, biochemical, and mouse-model evidence supports a target-amplification strategy for oral candidiasis, while also defining important limits for clinical translation.

• Amyloid Beta-Peptide (1-40): Assay Workflows

  2026-08-07

  Build controlled Aβ40 aggregation assays, ratiometric fibril imaging experiments, and cell-based neurotoxicity workflows with a defined human peptide model. This guide connects practical handling and troubleshooting to a dual-emissive ruthenium-probe strategy that distinguishes aggregation-dependent signals from assay background.

• Neticonazole Hydrochloride: Dual-Action Imidazole Antifungal

  2026-08-07

  Neticonazole Hydrochloride uniquely bridges antifungal and antitumor research, enabling streamlined protocols for both cutaneous candidiasis and colorectal cancer models. Explore optimized experimental workflows, troubleshooting strategies, and data-driven applications that leverage its dual mechanism.

• EDI3 Inhibition Reduces Viability in HER2-Resistant Breast C

  2026-08-06

  Keller et al. reveal that targeting EDI3, a key enzyme in choline metabolism, decreases cell viability and tumor growth in ER-HER2+ breast cancer cells resistant to HER2-targeted therapies. This work highlights EDI3 as a promising metabolic vulnerability and therapeutic target for overcoming resistance in this breast cancer subtype.

• MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition Insig

  2026-08-06

  MCC950 sodium (CRID3 sodium salt) is a potent, selective NLRP3 inflammasome inhibitor. This article details its mechanism, benchmark data, and translational applications in inflammatory disease research, with precise references and workflow guidance.

• Lipid Nanoparticle Delivery of Circular IL-23 mRNA Enhances

  2026-08-05

  This study demonstrates that combining lipid nanoparticle-encapsulated circular IL-23 mRNA with a platinum-modified STING agonist (MSA-2-Pt) produces synergistic antitumor responses in melanoma models. The approach highlights the potential of stabilized mRNA and advanced delivery for boosting tumor immunotherapy while mitigating systemic toxicity.

• 6-Thioguanine Induces Apoptosis via DNMT1 Inhibition in MCF-

  2026-08-05

  This study reveals that 6-thioguanine suppresses breast cancer cell proliferation by silencing DNA methyltransferase 1 (DNMT1) in MCF-7 cells. Transcriptomic and functional analyses demonstrate induction of FAS-mediated apoptosis and G2/M cell cycle arrest, highlighting a novel epigenetic mechanism for thioguanine in oncology research.

• Ertugliflozin (PF-04971729): Translational Advances in SGLT2

  2026-08-04

  Explore the scientific underpinnings and translational impact of Ertugliflozin (PF-04971729), a selective SGLT2 inhibitor. This article uniquely connects mechanistic insight with preclinical and clinical outcomes, providing actionable guidance for diabetes mellitus research.

• Z-VAD-FMK in Apoptosis Inhibition: Protocols, Innovations, a

  2026-08-04

  Z-VAD-FMK enables precise, reproducible inhibition of caspase-dependent apoptosis for advanced cell death pathway research. This article delivers actionable protocol enhancements, troubleshooting tips, and a translation of recent mechanistic breakthroughs in cancer cell assays, making it a must-read for researchers seeking robust, high-fidelity apoptosis modulation.

• Salvianolic Acid B Inhibits LH2 to Counter Pulmonary Fibrosi

  2026-08-03

  This study identifies Salvianolic acid B (Dan Shen Suan B) as a potent inhibitor of lysyl hydroxylase 2 (LH2), addressing pathological collagen cross-linking in pulmonary fibrosis. The findings reveal a targeted mechanism by which this natural compound disrupts extracellular matrix remodeling, offering a promising direction for antifibrotic research.

• High-Throughput Blood-Brain Barrier Model: Permeability Adva

  2026-08-03

  This study introduces a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction for more accurate CNS drug permeability prediction. The model demonstrates strong correlation with in vivo brain distribution and offers a validated, scalable platform for early-stage CNS drug candidate screening.

• Etomoxir (SKU A3404): Practical Solutions for Immunometaboli

  2026-08-02

  This article delivers scenario-driven guidance for researchers using Etomoxir (SKU A3404) in immunometabolic and metabolic disorder studies. It addresses common laboratory challenges, highlights evidence-based protocol optimization, and explains why APExBIO’s Etomoxir stands out for reliability and workflow compatibility.

• GDC-0994: ERK1/2 Inhibitor Workflows for Cancer & Liver Mode

  2026-08-01

  GDC-0994 enables precise dissection of ERK1/2 signaling in oncology and cholestatic liver models, offering researchers a potent tool for both mechanistic studies and therapeutic exploration. This article provides actionable protocols, troubleshooting strategies, and applies insights from recent research linking ERK1/2 inhibition to protection against phytoestrogen-induced cholestasis.

• A-769662: Potent AMPK Activator for Metabolic Research

  2026-07-31

  A-769662 is a highly selective, reversible small-molecule AMPK activator that enables precise dissection of cellular energy metabolism and fatty acid synthesis inhibition. New evidence shows AMPK activation by A-769662 suppresses autophagy initiation during energy stress, updating longstanding models. The compound’s dual action on AMPK and the 26S proteasome makes it a versatile tool for metabolic syndrome and type 2 diabetes research.

459 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page